Grafalon

Grafalon is a rabbit anti‑thymocyte globulin for human use, provided as a sterile solution for intravenous infusion. The active ingredient is anti‑T lymphocyte immunoglobulin derived from rabbit and is classified as an immunosuppressant. Marketed in the European Union and available only by prescription, Grafalon depletes circulating T cells to reduce the risk of graft rejection and other immune‑mediated complications in transplant recipients and patients with severe aplastic anemia.

Grafalon is indicated for several immunologic conditions where T‑cell suppression is required.

- Prevention of acute rejection in solid‑organ transplantation (kidney, liver, heart, lung). - Treatment of graft‑versus‑host disease following hematopoietic stem‑cell transplantation. - Management of severe aplastic anemia when other immunosuppressive therapies are insufficient. - Use as part of conditioning regimens for bone‑marrow transplantation to facilitate engraftment. - Adjunct therapy in certain autoimmune disorders under specialist supervision.

The safety profile of Grafalon includes a range of adverse events that vary in frequency and severity.

Common: - Fever, chills, or rigors occurring during or shortly after the intravenous infusion. - Nausea, vomiting, or abdominal discomfort that may be mild to moderate in intensity. - Transient changes in blood pressure, including episodes of hypertension or hypotension. - Headache, fatigue, or general malaise that usually resolves after treatment.

Serious: - Cytokine release syndrome, which can present with severe hypotension, respiratory distress, or organ dysfunction. - Serum‑sickness–like reactions, characterized by rash, arthralgia, fever, and lymphadenopathy. - Opportunistic or severe infections resulting from profound T‑cell depletion.

Clinicians should consider several precautions and warnings when prescribing Grafalon to minimize risks and ensure appropriate patient monitoring.

- Baseline assessment of infection status; avoid use in active uncontrolled infections. - Monitoring of complete blood count and lymphocyte levels before, during, and after therapy. - Pre‑medication with antipyretics, antihistamines, or corticosteroids to reduce infusion‑related reactions. - Caution in patients with cardiovascular disease due to possible hemodynamic changes. - Evaluate renal and hepatic function, as dose adjustments may be required. - Pregnancy and breastfeeding status should be assessed; safety data are limited. - Long‑term immunosuppression may increase risk of malignancies; regular surveillance is advised.

Grafalon may interact with other medications, influencing its efficacy or safety profile; awareness of these interactions guides clinical decisions.

Avoid: - Live attenuated vaccines, because immunosuppression can lead to uncontrolled infection. - Concurrent use of other potent T‑cell depleting agents (e.g., alemtuzumab) without specialist guidance. - High‑dose corticosteroids that may exacerbate infection risk when combined.

Use with caution: - Antimicrobial prophylaxis (e.g., antivirals, antifungals) should be tailored to infection risk. - Calcineurin inhibitors (cyclosporine, tacrolimus) may require dose adjustments due to additive nephrotoxicity. - Hematopoietic growth factors (G‑CSF) may be needed to support neutrophil recovery. - Diuretics or antihypertensives, as blood pressure fluctuations can occur during infusion.